Fuzhegn Nizeng Decoction

PreclinicalSmall molecule

Fuzhegn Nizeng Decoction is one of 3 small molecule programs targeting Intraepithelial Neoplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intraepithelial NeoplasiaActive, not recruiting

Intraepithelial NeoplasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Intraepithelial Neoplasia

#DrugCompanyPhaseTrials

Aldara

BBausch Health Americas, Inc.

Nolvadex

1 3

Fuzhegn Nizeng Decoction

PPeking University First Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intraepithelial Neoplasia1 trial

Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Recruiting·PPeking University First Hospital·N/A·NCT06324825·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fuzhegn Nizeng Decoction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fuzhegn Nizeng Decoction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fuzhegn Nizeng Decoction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University First Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPeking University First Hospital

Fuzhegn Nizeng Decoction

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intraepithelial Neoplasia1 trial

References

Drug Info

Quick Facts

Related News